What's Hot

    Marrying Innovation and Sustainability: Eviosys Launches Revolutionary Metal Closure ‘Horizon’ Enabling Brands to Adopt Mono-Material Packaging

    September 21, 2023

    Global Citizen Forum Unveils Earth Age – the Second Chapter of the Butterfly Effect Trilogy

    September 20, 2023

    HotelRunner Acquires PayPad in a Strategic Move Into On-Premise Sales Operations

    September 19, 2023
    Facebook X (Twitter) Instagram
    Niger LiveNiger Live
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Niger LiveNiger Live
    Home » Korea to receive 40 million COVID vaccines from Moderna
    Health

    Korea to receive 40 million COVID vaccines from Moderna

    March 4, 2021
    Facebook Twitter Pinterest Reddit Telegram LinkedIn Tumblr VKontakte WhatsApp Email

    Moderna Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, confirmed that the Company has entered into a supply agreement with the government of the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine to support the government’s aim of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, deliveries would begin in May 2021.

    Korea to receive 40 million COVID vaccines from Moderna
    Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. 

    The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

    Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit their website.

    Share. Facebook Twitter Pinterest LinkedIn Reddit Email

    Related Posts

    New research warns of liver risk from daily soda consumption

    September 6, 2023

    Sheesha cafes are a lethal mix of health risks and idle talk

    September 6, 2023

    Blue Zone centenarians’ longevity linked to high-carb diet

    September 1, 2023

    Cholesterol – the silent killer and Its Impact on hearing

    August 29, 2023
    Latest News

    From India to Brazil, leadership transition marks G20 Summit’s conclusion

    September 11, 2023

    African Union Inducted into G20 on India’s Initiative

    September 9, 2023

    Biden and Modi cement ties as India ascends global stage

    September 9, 2023
    © 2021 Niger Live | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.